Pediatric Patients Undergoing Allogeneic Cord Blood Transplantation. Clinical Trial
Official title:
Eltrombopag for Enhancing Platelet Engraftment in Pediatric Patients Undergoing Cord Blood Transplantation
Platelet recovery is significantly hampered following umbilical cord blood transplantation
(UCB). Thus, after UCB transplantations, patients are platelet transfusion-dependent for
prolong periods of time.
Eltrombopag is a thrombopoietin-receptor agonist that initiates thrombopoietin-receptor
signaling and thereby induces proliferation and maturation of megakaryocytes.
We will evaluate the safety and efficacy of eltrombopag for enhancing platelet engraftment
in pediatric patients undergoing cord blood transplantation.
n/a
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment